Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Amgen Inc. is conducting a Phase 1b/2 clinical study titled A Phase 1b/2 Study Evaluating the Safety, Tolerability, Efficacy, and Pharmacokinetics of Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer (FORTITUDE-103). The study aims to assess the safety, tolerability, and efficacy of bemarituzumab combined with other anti-cancer therapies, focusing on patients with advanced gastric or gastroesophageal junction cancer. This research is significant as it explores potential new treatment combinations for a challenging cancer type.
Intervention/Treatment: The study tests bemarituzumab, an intravenous drug, in combination with CAPOX (a mix of oxaliplatin and capecitabine), SOX (a mix of oxaliplatin and S-1), and nivolumab. These combinations aim to enhance treatment efficacy for advanced gastric cancer.
Study Design: This interventional study is non-randomized and follows a sequential intervention model. It is unmasked, meaning both researchers and participants know the treatment being administered. The primary purpose is basic science, focusing on understanding the treatment’s effects.
Study Timeline: The study began on May 17, 2022, and is currently recruiting participants. The last update was submitted on July 18, 2025. These dates are crucial as they indicate the study’s progress and ongoing nature.
Market Implications: The ongoing study could influence Amgen’s stock performance positively if results show promising outcomes, potentially boosting investor confidence. The study’s focus on a challenging cancer type may also set Amgen apart from competitors, highlighting its commitment to innovative cancer therapies.
The study is ongoing, with further details available on the ClinicalTrials portal.